Speak about a lucky charm.
Drugs like Ozempic — which mimic the appetite-suppressing GLP-1 hormone the body naturally produces after eating — have been shown to spur weight reduction in addition to ease knee osteoarthritis pain, calm skin conditions and lower the chance of dementia.
Now, a global team of researchers has found more evidence that individuals also booze quite a bit less when taking these meds.
“GLP-1 [drugs] have been shown to treat obesity and reduce the chance of multiple obesity-related complications,” said Professor Carel le Roux of University College Dublin in Ireland.
“The helpful effects beyond obesity, similar to on alcohol intake, are being actively studied, with some promising results.”
Le Roux’s team analyzed data from 262 chubby or obese adults prescribed liraglutide or semaglutide for weight reduction at a clinic in Dublin.
Semaglutide is sold as Ozempic to treat Type 2 diabetes and as Wegovy for obesity.
Saxenda and Victoza contain liraglutide. Saxenda is for weight reduction, while Victoza is for diabetes.
Volunteers reported their alcohol habits before the study began and were split into three groups — there have been 31 non-drinkers, 52 rare drinkers (lower than 10 drinks every week) and 179 regular drinkers (over 10 every week).
A lot of the participants were female, the typical age was 46 and the typical weight was 216 kilos.
The researchers followed 188 of the 262 patients for a median of 4 months of treatment. Not one of the participants drank greater than usual during that point.
Average alcohol intake decreased from 11.3 to 4.3 drinks every week, a discount of virtually two-thirds.
Among the many regular drinkers, consumption declined from 23.2 to 7.8 drinks every week.
The findings were published in January within the journal Diabetes, Obesity and Metabolism and are as a result of be presented in the approaching days on the European Congress on Obesity in Malaga, Spain.
“The precise mechanism of how GLP-1 [drugs] reduce alcohol intake continues to be being investigated, but it surely is assumed to involve curbing cravings for alcohol that arise in subcortical areas of the brain that are usually not under conscious control,” le Roux said. “Thus, patients report the results are ‘effortless.’”
Le Roux reported that the alcohol reduction from GLP-1s mirrors the outcomes of nalmefene, a drug used to treat alcohol dependence in Europe.
Harmful alcohol use accounts for about 2.6 million deaths a 12 months, 4.7% of all global deaths.
Treatment typically involves counseling, similar to behavioral therapy, and medications that reduce the urge to drink. Nonetheless, relapse rates are high.
GLP-1s are usually not a cure-all, to make certain. Unintended effects can include gastrointestinal issues like nausea, and fewer often, hair loss and skin pain. In very rare cases, blindness and behavioral changes can occur.
Speak about a lucky charm.
Drugs like Ozempic — which mimic the appetite-suppressing GLP-1 hormone the body naturally produces after eating — have been shown to spur weight reduction in addition to ease knee osteoarthritis pain, calm skin conditions and lower the chance of dementia.
Now, a global team of researchers has found more evidence that individuals also booze quite a bit less when taking these meds.
“GLP-1 [drugs] have been shown to treat obesity and reduce the chance of multiple obesity-related complications,” said Professor Carel le Roux of University College Dublin in Ireland.
“The helpful effects beyond obesity, similar to on alcohol intake, are being actively studied, with some promising results.”
Le Roux’s team analyzed data from 262 chubby or obese adults prescribed liraglutide or semaglutide for weight reduction at a clinic in Dublin.
Semaglutide is sold as Ozempic to treat Type 2 diabetes and as Wegovy for obesity.
Saxenda and Victoza contain liraglutide. Saxenda is for weight reduction, while Victoza is for diabetes.
Volunteers reported their alcohol habits before the study began and were split into three groups — there have been 31 non-drinkers, 52 rare drinkers (lower than 10 drinks every week) and 179 regular drinkers (over 10 every week).
A lot of the participants were female, the typical age was 46 and the typical weight was 216 kilos.
The researchers followed 188 of the 262 patients for a median of 4 months of treatment. Not one of the participants drank greater than usual during that point.
Average alcohol intake decreased from 11.3 to 4.3 drinks every week, a discount of virtually two-thirds.
Among the many regular drinkers, consumption declined from 23.2 to 7.8 drinks every week.
The findings were published in January within the journal Diabetes, Obesity and Metabolism and are as a result of be presented in the approaching days on the European Congress on Obesity in Malaga, Spain.
“The precise mechanism of how GLP-1 [drugs] reduce alcohol intake continues to be being investigated, but it surely is assumed to involve curbing cravings for alcohol that arise in subcortical areas of the brain that are usually not under conscious control,” le Roux said. “Thus, patients report the results are ‘effortless.’”
Le Roux reported that the alcohol reduction from GLP-1s mirrors the outcomes of nalmefene, a drug used to treat alcohol dependence in Europe.
Harmful alcohol use accounts for about 2.6 million deaths a 12 months, 4.7% of all global deaths.
Treatment typically involves counseling, similar to behavioral therapy, and medications that reduce the urge to drink. Nonetheless, relapse rates are high.
GLP-1s are usually not a cure-all, to make certain. Unintended effects can include gastrointestinal issues like nausea, and fewer often, hair loss and skin pain. In very rare cases, blindness and behavioral changes can occur.
